Cargando…

Single‐nucleotide polymorphisms in cachexia‐related genes: Can they optimize the treatment of cancer cachexia?

Detalles Bibliográficos
Autores principales:	Ishida, Junichi, Saitoh, Masakazu, Springer, Jochen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5476860/ https://www.ncbi.nlm.nih.gov/pubmed/28631414 http://dx.doi.org/10.1002/jcsm.12214

Ejemplares similares

Irisin – a myokine potentially bridging muscle and fat tissue in cachexia
por: Konishi, Masaaki, et al.
Publicado: (2015)

Novel mechanism of ghrelin therapy for cachexia
por: Hatanaka, Michiyoshi, et al.
Publicado: (2015)

Evidence for an effect of ACE inhibitors on cancer cachexia
por: Schanze, Nancy, et al.
Publicado: (2012)

Nutrition in cachexia: from bench to bedside
por: Konishi, Masaaki, et al.
Publicado: (2016)

Physical activity for the prevention and treatment of sarcopenic obesity
por: Saitoh, Masakazu, et al.
Publicado: (2017)

Is cardiac wasting accompanied by skeletal muscle loss in breast cancer patients receiving anticancer treatment?
por: Ishida, Junichi, et al.
Publicado: (2017)

Open source in cachexia?
por: Stemmler, Britta, et al.
Publicado: (2015)

Considering technique of assessment and method for normalizing skeletal muscle mass
por: Saitoh, Masakazu, et al.
Publicado: (2017)

Does COVID‐19‐related cachexia mimic cancer‐related cachexia? Examining mechanisms, clinical biomarkers, and potential targets for clinical management
por: Kumar, Nagi B.
Publicado: (2021)

Concern regarding quality and quality of muscle
por: Saitoh, Masakazu, et al.
Publicado: (2015)

The concept that focuses on oral motor and feeding function in cancer patients with muscle wasting: Skeletal muscle mass is associated with severe dysphagia in cancer patients
por: Saitoh, Masakazu, et al.
Publicado: (2016)

Growth differentiation factor‐15 as a prognostic biomarker in cancer patients
por: Ishida, Junichi, et al.
Publicado: (2016)

Clinical perspective for wasting in diaphragm, an ever‐trained muscle
por: Konishi, Masaaki, et al.
Publicado: (2016)

Cachexia research in Japan: facts and numbers on prevalence, incidence and clinical impact
por: Konishi, Masaaki, et al.
Publicado: (2016)

Identification of Cause of Posttransplant Cachexia by PCR
por: Guitard, Joelle, et al.
Publicado: (2012)

Bile acids for cachexia therapy: Reply to the letter by Shailendra Kapoor: Ursodeoxycholic acid and its emerging role in attenuation of tumor growth in gastrointestinal malignancies
por: Tschirner, Anika, et al.
Publicado: (2012)

Cardiac Cachexia - A Window to the Wasting Disorders
por: Coats, Andrew J Stewart
Publicado: (2018)

Induction of cachexia in mice
por: Tisdale, M
Publicado: (1999)

Comment on 'Hand grip strength‐based cachexia index as a predictor of cancer cachexia and prognosis in patients with cancer' by Xie et al.
por: Ding, Ping'an, et al.
Publicado: (2023)

Cardiac cachexia: hic et nunc
por: Loncar, Goran, et al.
Publicado: (2016)

Biomarkers for cancer cachexia: where do we stand?
por: Palus, Sandra, et al.
Publicado: (2020)

Cardiac muscle wasting in individuals with cancer cachexia
por: Barkhudaryan, Anush, et al.
Publicado: (2017)

Breakthrough in cachexia treatment through a novel selective androgen receptor modulator?!
por: Thum, Thomas, et al.
Publicado: (2011)

The 10th year of the Journal of Cachexia, Sarcopenia and Muscle
por: Anker, Markus S., et al.
Publicado: (2020)

MT‐102 prevents tissue wasting and improves survival in a rat model of severe cancer cachexia
por: Pötsch, Mareike S., et al.
Publicado: (2020)

Biomarkers and mechanisms associated with cancer‐induced cardiac cachexia: A systematic review
por: Bagnall, Lisa, et al.
Publicado: (2023)

Ursodeoxycholic acid treatment in a rat model of cancer cachexia
por: Tschirner, Anika, et al.
Publicado: (2011)

Hypermetabolism: should cancer types, pathological stages and races be considered in assessing metabolism and could elevated resting energy expenditure be the therapeutic target in patients with advanced cancer?
por: Ishida, Junichi, et al.
Publicado: (2015)

Cachexia in heart disease: highlights from the ESC 2010
por: Kung, Thomas, et al.
Publicado: (2011)

The atypical β‐blocker S‐oxprenolol reduces cachexia and improves survival in a rat cancer cachexia model
por: Yuan, Luping, et al.
Publicado: (2022)

Loss of muscle mass: current developments in cachexia and sarcopenia focused on biomarkers and treatment
por: Drescher, Cathleen, et al.
Publicado: (2015)

Formoterol in the treatment of experimental cancer cachexia: effects on heart function
por: Toledo, Míriam, et al.
Publicado: (2014)

Comment on ‘The expression landscape of cachexia‐inducing factors in human cancers’ by Freire et al.
por: Xie, Longxiang, et al.
Publicado: (2021)

Comment on ‘The expression landscape of cachexia‐inducing factors in human cancers’ by Freire et al.
por: Song, Shiyu, et al.
Publicado: (2020)

Comment on ‘COVID‐19: a major cause of cachexia and sarcopenia’ by Morley et al.
por: Zhou, Ling, et al.
Publicado: (2020)

Cancer cachexia.
por: Tisdale, M. J.
Publicado: (1991)

Cancer cachexia
por: Martignoni, Marcus E, et al.
Publicado: (2003)

Cancer cachexia
por: Dhanapal, Raghu, et al.
Publicado: (2011)

Ghrelin for cachexia
por: Akamizu, Takashi, et al.
Publicado: (2010)

Inflammation in Cachexia
por: Seelaender, M., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_uek87ib9pf2fkl0bu68ur6o0vp